Crizotinib as Salvage and Maintenance With Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma

The NPM-ALK fusion protein is found in ALK+ anaplastic large cell lymphomas harboring the t(2;5) chromosomal translocation. Patients harboring ALK translocations typically have an excellent prognosis with conventional chemotherapy and a reported 5-year survival rate of 70%. Although most patients with ALK+ anaplastic large cell lymphoma have a good prognosis, some patients do not respond to standard therapies. In patients with refractory anaplastic large cell lymphoma who can achieve remission, allogeneic stem cell transplant is a potentially curative option. This article describes a patient with refractory ALK+ anaplastic large cell lymphoma who experienced a complete response to the ALK inhibitor crizotinib and then underwent an allogeneic stem cell transplant followed by crizotinib maintenance therapy.

Target Audience

This activity has been designated to meet the educational needs of physicians and nurses involved in the management of patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Discuss the clinical activity of crizotinib in the management of patients with anaplastic large cell lymphoma
Additional information
Supporters: 

No commercial support was received for this article.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician
Course opens: 
03/10/2014
Course expires: 
03/10/2015
Cost:
$0.00

James M. Cleary, MD, PhD
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts

Scott Rodig
Brigham and Women’s Hospital, Harvard Medical School
Boston, Massachusetts

Paul M. Barr
University of Rochester Medical Center, University of Rochester
Rochester, New York

Atul B. Shinagare
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts

Jeffrey W. Clark
Massachusetts General Hospital, Harvard Medical School
Boston, Massachusetts

Geoffrey I. Shapiro
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts

Philippe Armand
Dana-Farber Cancer Institute, Harvard Medical School
Boston, Massachusetts

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Physician

Accreditation Period

Course opens: 
03/10/2014
Course expires: 
03/10/2015

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing